CreativeOne Wealth LLC Lowers Holdings in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

CreativeOne Wealth LLC lowered its stake in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 18.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,365 shares of the company’s stock after selling 5,127 shares during the period. CreativeOne Wealth LLC owned 0.55% of Invesco Biotechnology & Genome ETF worth $1,488,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of PBE. JPMorgan Chase & Co. lifted its stake in Invesco Biotechnology & Genome ETF by 30.0% in the 4th quarter. JPMorgan Chase & Co. now owns 650 shares of the company’s stock worth $43,000 after purchasing an additional 150 shares in the last quarter. Millstone Evans Group LLC bought a new position in Invesco Biotechnology & Genome ETF during the fourth quarter valued at approximately $64,000. Jones Financial Companies Lllp grew its holdings in Invesco Biotechnology & Genome ETF by 52.9% during the 4th quarter. Jones Financial Companies Lllp now owns 2,315 shares of the company’s stock valued at $154,000 after buying an additional 801 shares in the last quarter. Farther Finance Advisors LLC purchased a new stake in shares of Invesco Biotechnology & Genome ETF during the 4th quarter worth approximately $161,000. Finally, Jane Street Group LLC bought a new position in shares of Invesco Biotechnology & Genome ETF during the 3rd quarter valued at approximately $295,000.

Invesco Biotechnology & Genome ETF Stock Performance

Shares of PBE opened at $59.97 on Wednesday. Invesco Biotechnology & Genome ETF has a fifty-two week low of $54.52 and a fifty-two week high of $72.84. The company’s fifty day moving average is $64.53 and its 200 day moving average is $67.35. The stock has a market capitalization of $215.89 million, a PE ratio of 21.05 and a beta of 0.83.

Invesco Biotechnology & Genome ETF Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.